Loading clinical trials...

A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome) | Clinical Trials | Clareo Health

COMPLETED

A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)

A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA)

NCT05523206•Sanguine Biosciences

View on ClinicalTrials.gov

Summary

This protocol is a decentralized, single cohort, natural history and biomarker study enrolling up to 20 participants with MPS IIIA (Sanfilippo syndrome). At least 10 participants (\~50%) must be less than four years old at the time of the Parent/LAR consent. The study will have a screening process and 7 study visits, e.g. home visits, that will consist of serum collection and completion of a remote assessment of the Vineland Adaptive Behavior Scales 3rd Edition (Vineland-3) MPS IIIA remains a devastating disease with a high unmet medical need. There is currently a limited number of available data to adequately characterize the progression of the disease. Analysis of blood biospecimens and adaptive behavior in this study will help researchers better understand the clinical progression of MPS IIIA. A better understanding of disease progression may assist in developing novel therapies for rare genetic disorders.

Eligibility

Age

0 - 13 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age of enrollment is as follows:
•1. All participants must be between 4 months and \< 14 years at time of consent
•2. At least 10 participants (ie, approx. 50% of expected total population) must be between 4 months old and \< 4 years old at the time of consent
•The participant has a confirmed diagnosis of Mucopolysaccharidosis Type IIIA (MPS IIIA) (i.e., Sanfilippo syndrome) based on at least 2 out of the 3 following criteria:
•1. Documented reduced N-sulphoglucosamine sulphohydrolase (SGSH) activity in plasma, white blood cells, and/or skin fibroblasts consistent with MPS IIIA (10% or less of the lower limit of the normal range based on the testing laboratory)
•2. Documented likely pathogenic variant of the SGSH gene
•3. Documented elevated heparan sulfate levels in urine and/or blood Participants and their families are willing to complete 7 blood draws and 7 Vineland-3 collections

Exclusion Criteria

•Known history of HIV, hepatitis, or other infectious diseases
•Taken an investigational product in the last 30 days
•Experienced excess blood loss, including blood donation, defined as 80 mL in the last month or 160 mL in the previous two months
•Undergone an MPS IIIA gene therapy at any time unless prior Sponsor or designee's approval has been received
•Documented loss of activity of sulfatases other than N-sulphoglucosamine sulphohydrolase (SGSH), indicating multiple sulfatase deficiency
•Known genetic or acquired disorder associated with developmental delay, seizures or other significant CNS dysfunction that would be expected to confound the clinical or biomarker assessments

Locations (1)

Sanguine Biosciences, Inc.

Woburn, Massachusetts, United States

Key Dates

Start Date

September 27, 2022

Primary Completion Date

December 19, 2024

Completion Date

January 28, 2025

Last Updated

January 30, 2025

Enrollment

ACTUAL participants

Conditions

Mucopolysaccharidosis III-A

Interventions

No intervention

OTHER